Aberrant lipid metabolism promotes prostate cancer: Role in cell survival under hypoxia and extracellular vesicles biogenesis

International Journal of Molecular Sciences

Volumn 17, Issue 7, 2016, Pages

  Deep, Gagan ^a   Schlaepfer, Isabel R ^b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Carnitine palmitoyltransferase (CPT1); Extracellular vesicles; Fatty acid oxidation; Hypoxia; Lipogenesis; Prostate cancer; Re oxygenation

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; GLUTAMINE; GROWTH HORMONE; HYPOXIA INDUCIBLE FACTOR;

BIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL COMMUNICATION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; EXOSOME; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HUMAN; LIPID METABOLISM; LIPID OXIDATION; LIPID STORAGE; LIPOGENESIS; PROSTATE CANCER; REOXYGENATION; REVIEW; ANIMAL; CELL HYPOXIA; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; CELL HYPOXIA; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; HUMANS; LIPID METABOLISM; MALE; OXIDATIVE STRESS; PROSTATIC NEOPLASMS;

EID: 84977511570     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17071061     Document Type: Review

References (102)

1. Yue, S.; Li, J.; Lee, S.Y.; Lee, H.J.; Shao, T.; Song, B.; Cheng, L.; Masterson, T.A.; Liu, X.; Ratliff, T.L.; et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014, 19, 393-406. [CrossRef] [PubMed]
2. Fritz, V.; Benfodda, Z.; Rodier, G.; Henriquet, C.; Iborra, F.; Avances, C.; Allory, Y.; de la Taille, A.; Culine, S.; Blancou, H.; et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol. Cancer Ther. 2010, 9, 1740-1754. [CrossRef] [PubMed]
3. Rysman, E.; Brusselmans, K.; Scheys, K.; Timmermans, L.; Derua, R.; Munck, S.; van Veldhoven, P.P.; Waltregny, D.; Daniels, V.W.; Machiels, J.; et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010, 70, 8117-8126. [CrossRef] [PubMed]
4. Schlaepfer, I.R.; Nambiar, D.K.; Ramteke, A.; Kumar, R.; Dhar, D.; Agarwal, C.; Bergman, B.; Graner, M.; Maroni, P.; Singh, R.P.; et al. Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation. Oncotarget 2015, 6, 22836-22856. [CrossRef] [PubMed]
5. Warburg, O. On the origin of cancer cells. Science 1956, 123, 309-314. [CrossRef] [PubMed]
6. Medes, G.; Thomas, A.; Weinhouse, S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953, 13, 27-29. [PubMed]
7. Kuhajda, F.P. Fatty acid synthase and cancer: New application of an old pathway. Cancer Res. 2006, 66, 5977-5980. [CrossRef] [PubMed]
8. Swinnen, J.V.; van Veldhoven, P.P.; Esquenet, M.; Heyns,W.; Verhoeven, G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996, 137, 4468-4474. [PubMed]
9. Cahoon, E.K.; Kitahara, C.M.; Ntowe, E.; Bowen, E.M.; Doody, M.M.; Alexander, B.H.; Lee, T.; Little, M.P.; Linet, M.S.; Freedman, D.M. Female estrogen-related factors and incidence of basal cell carcinoma in a nationwide US cohort. J. Clin. Oncol. 2015, 33, 4058-4065. [CrossRef] [PubMed]
10. Chlebowski, R.T.; Anderson, G.L.; Gass, M.; Lane, D.S.; Aragaki, A.K.; Kuller, L.H.; Manson, J.E.; Stefanick, M.L.; Ockene, J.; Sarto, G.E.; et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304, 1684-1692. [CrossRef] [PubMed]
11. Manson, J.E.; Chlebowski, R.T.; Stefanick, M.L.; Aragaki, A.K.; Rossouw, J.E.; Prentice, R.L.; Anderson, G.; Howard, B.V.; Thomson, C.A.; LaCroix, A.Z.; et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA 2013, 310, 1353-1368. [CrossRef] [PubMed]
12. Schlaepfer, I.R.; Glode, L.M.; Hitz, C.A.; Pac, C.T.; Boyle, K.E.; Maroni, P.; Deep, G.; Agarwal, R.; Lucia, S.M.; Cramer, S.D.; et al. Inhibition of lipid oxidation increases glucose metabolism and enhances 2-deoxy-2-[18F]Fluoro-D-glucose uptake in prostate cancer mouse xenografts. Mol. Imaging Biol. 2015, 17, 529-538. [CrossRef] [PubMed]
13. Zadra, G.; Photopoulos, C.; Loda, M. The fat side of prostate cancer. Biochim. Biophys. Acta 2013, 1831, 1518-1532. [CrossRef] [PubMed]
14. Carlsson, S.; Vickers, A.J.; Roobol, M.; Eastham, J.; Scardino, P.; Lilja, H.; Hugosson, J. Prostate cancer screening: Facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J. Clin. Oncol. 2012, 30, 2581-2584. [CrossRef] [PubMed]
15. Knudsen, K.E.; Scher, H.I. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin. Cancer Res. 2009, 15, 4792-4798. [CrossRef] [PubMed]
16. Dehm, S.M.; Tindall, D.J. Alternatively spliced androgen receptor variants. Endocr. Relat. Cancer 2011, 18, R183-R196. [CrossRef] [PubMed]
17. Swinnen, J.V.; Brusselmans, K.; Verhoeven, G. Increased lipogenesis in cancer cells: New players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9, 358-365. [CrossRef] [PubMed]
18. Suburu, J.; Chen, Y.Q. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat. 2012, 98, 1-10. [CrossRef] [PubMed]
19. Ettinger, S.L.; Sobel, R.; Whitmore, T.G.; Akbari, M.; Bradley, D.R.; Gleave, M.E.; Nelson, C.C. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004, 64, 2212-2221. [CrossRef] [PubMed]
20. Beloribi-Djefaflia, S.; Vasseur, S.; Guillaumond, F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016, 5, e189. [CrossRef] [PubMed]
21. Vavere, A.L.; Kridel, S.J.; Wheeler, F.B.; Lewis, J.S. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J. Nucl. Med. 2008, 49, 327-334. [CrossRef] [PubMed]
22. Menendez, J.A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7, 763-777. [CrossRef] [PubMed]
23. Patra, S.K. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim. Biophys. Acta 2008, 1785, 182-206. [CrossRef] [PubMed]
24. Scaglia, N.; Chisholm, J.W.; Igal, R.A. Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: Role of AMPK. PLoS ONE 2009, 4, e6812. [CrossRef] [PubMed]
25. Schlaepfer, I.R.; Hitz, C.A.; Gijon, M.A.; Bergman, B.C.; Eckel, R.H.; Jacobsen, B.M. Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel. Mol. Cell. Endocrinol. 2012, 363, 111-121. [CrossRef] [PubMed]
26. Nomura, D.K.; Long, J.Z.; Niessen, S.; Hoover, H.S.; Ng, S.W.; Cravatt, B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140, 49-61. [CrossRef] [PubMed]
27. Samudio, I.; Harmancey, R.; Fiegl, M.; Kantarjian, H.; Konopleva, M.; Korchin, B.; Kaluarachchi, K.; Bornmann, W.; Duvvuri, S.; Taegtmeyer, H.; et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Investig. 2010, 120, 142-156. [CrossRef] [PubMed]
28. Harper, M.E.; Antoniou, A.; Villalobos-Menuey, E.; Russo, A.; Trauger, R.; Vendemelio, M.; George, A.; Bartholomew, R.; Carlo, D.; Shaikh, A.; et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 2002, 16, 1550-1557. [CrossRef] [PubMed]
29. Pike, L.S.; Smift, A.L.; Croteau, N.J.; Ferrick, D.A.; Wu, M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 2011, 1807, 726-734. [CrossRef] [PubMed]
30. Beltran, H.; Prandi, D.; Mosquera, J.M.; Benelli, M.; Puca, L.; Cyrta, J.; Marotz, C.; Giannopoulou, E.; Chakravarthi, B.V.; Varambally, S.; et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 2016, 22, 298-305. [CrossRef] [PubMed]
31. Gatza, M.L.; Silva, G.O.; Parker, J.S.; Fan, C.; Perou, C.M. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat. Genet. 2014, 46, 1051-1059. [CrossRef] [PubMed]
32. Grasso, C.S.; Wu, Y.M.; Robinson, D.R.; Cao, X.; Dhanasekaran, S.M.; Khan, A.P.; Quist, M.J.; Jing, X.; Lonigro, R.J.; Brenner, J.C.; et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487, 239-243. [CrossRef] [PubMed]
33. Park, J.H.; Vithayathil, S.; Kumar, S.; Sung, P.L.; Dobrolecki, L.E.; Putluri, V.; Bhat, V.B.; Bhowmik, S.K.; Gupta, V.; Arora, K.; et al. Fatty acid oxidation-driven Src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer. Cell Rep. 2016, 14, 2154-2165. [CrossRef] [PubMed]
34. Varambally, S.; Yu, J.; Laxman, B.; Rhodes, D.R.; Mehra, R.; Tomlins, S.A.; Shah, R.B.; Chandran, U.; Monzon, F.A.; Becich, M.J.; et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8, 393-406. [CrossRef] [PubMed]
35. Ricciardi, M.R.; Mirabilii, S.; Allegretti, M.; Licchetta, R.; Calarco, A.; Torrisi, M.R.; Foa, R.; Nicolai, R.; Peluso, G.; Tafuri, A. Targeting the leukemia cell metabolism by the CPT1_ inhibition: Functional preclinical effects in leukemias. Blood 2015, 126, 1925-1929. [CrossRef] [PubMed]
36. Zaugg, K.; Yao, Y.; Reilly, P.T.; Kannan, K.; Kiarash, R.; Mason, J.; Huang, P.; Sawyer, S.K.; Fuerth, B.; Faubert, B.; et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011, 25, 1041-1051. [CrossRef] [PubMed]
37. Hernlund, E.; Ihrlund, L.S.; Khan, O.; Ates, Y.O.; Linder, S.; Panaretakis, T.; Shoshan, M.C. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int. J. Cancer 2008, 123, 476-483. [CrossRef] [PubMed]
38. Schlaepfer, I.R.; Rider, L.; Rodrigues, L.U.; Gijon, M.A.; Pac, C.T.; Romero, L.; Cimic, A.; Sirintrapun, S.J.; Glode, L.M.; Eckel, R.H.; et al. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol. Cancer Ther. 2014, 13, 2361-2371. [CrossRef] [PubMed]
39. Carracedo, A.; Cantley, L.C.; Pandolfi, P.P. Cancer metabolism: Fatty acid oxidation in the limelight. Nat. Rev. Cancer 2013, 13, 227-232. [CrossRef] [PubMed]
40. Epstein, J.I.; Amin, M.B.; Beltran, H.; Lotan, T.L.; Mosquera, J.M.; Reuter, V.E.; Robinson, B.D.; Troncoso, P.; Rubin, M.A. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 2014, 38, 756-767. [CrossRef] [PubMed]
41. Robinson, D.; van Allen, E.M.; Wu, Y.M.; Schultz, N.; Lonigro, R.J.; Mosquera, J.M.; Montgomery, B.; Taplin, M.E.; Pritchard, C.C.; Attard, G.; et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015, 161, 1215-1228. [CrossRef] [PubMed]
42. Shappell, S.B.; Boeglin,W.E.; Olson, S.J.; Kasper, S.; Brash, A.R. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am. J. Pathol. 1999, 155, 235-245. [CrossRef]
43. Tang, S.; Bhatia, B.; Maldonado, C.J.; Yang, P.; Newman, R.A.; Liu, J.; Chandra, D.; Traag, J.; Klein, R.D.; Fischer, S.M.; et al. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J. Biol. Chem. 2002, 277, 16189-16201. [CrossRef] [PubMed]
44. Sriburi, R.; Jackowski, S.; Mori, K.; Brewer, J.W. XBP1: A link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J. Cell Biol. 2004, 167, 35-41. [CrossRef] [PubMed]
45. Abozguia, K.; Clarke, K.; Lee, L.; Frenneaux, M. Modification of myocardial substrate use as a therapy for heart failure. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3, 490-498. [CrossRef] [PubMed]
46. DeGrado, T.R.; Bhattacharyya, F.; Pandey, M.K.; Belanger, A.P.;Wang, S. Synthesis and preliminary evaluation of 18-18F-fluoro-4-thia-oleate as a PET probe of fatty acid oxidation. J. Nucl. Med. 2010, 51, 1310-1317. [CrossRef] [PubMed]
47. Schmidt-Schweda, S.; Holubarsch, C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin. Sci. 2000, 99, 27-35. [CrossRef] [PubMed]
48. Lionetti, V.; Stanley, W.C.; Recchia, F.A. Modulating fatty acid oxidation in heart failure. Cardiovasc. Res. 2011, 90, 202-209. [CrossRef] [PubMed]
49. Ashrafian, H.; Horowitz, J.D.; Frenneaux, M.P. Perhexiline. Cardiovasc. Drug Rev. 2007, 25, 76-97. [CrossRef] [PubMed]
50. Maly, D.J.; Papa, F.R. Druggable sensors of the unfolded protein response. Nat. Chem. Biol. 2014, 10, 892-901. [CrossRef] [PubMed]
51. Feldman, D.E.; Chauhan, V.; Koong, A.C. The unfolded protein response: A novel component of the hypoxic stress response in tumors. Mol. Cancer Res. 2005, 3, 597-605. [CrossRef] [PubMed]
52. Holz, M.S.; Janning, A.; Renne, C.; Gattenlohner, S.; Spieker, T.; Brauninger, A. Induction of endoplasmic reticulum stress by sorafenib and activation of NF-_B by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines. Mol. Cancer Ther. 2013, 12, 173-183. [CrossRef] [PubMed]
53. Koong, A.C.; Chauhan, V.; Romero-Ramirez, L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol. Ther. 2006, 5, 756-759. [CrossRef] [PubMed]
54. Wang, D.;Wei, Y.; Pagliassotti, M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006, 147, 943-951. [CrossRef] [PubMed]
55. Wei, Y.;Wang, D.; Pagliassotti, M.J. Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells. Mol. Cell. Biochem. 2007, 303, 105-113. [CrossRef] [PubMed]
56. Wei, Y.; Wang, D.; Gentile, C.L.; Pagliassotti, M.J. Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells. Mol. Cell. Biochem. 2009, 331, 31-40. [CrossRef] [PubMed]
57. Milosevic, M.; Warde, P.; Menard, C.; Chung, P.; Toi, A.; Ishkanian, A.; McLean, M.; Pintilie, M.; Sykes, J.; Gospodarowicz, M.; et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin. Cancer Res. 2012, 18, 2108-2114. [CrossRef] [PubMed]
58. Ragnum, H.B.; Vlatkovic, L.; Lie, A.K.; Axcrona, K.; Julin, C.H.; Frikstad, K.M.; Hole, K.H.; Seierstad, T.; Lyng, H. The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. Br. J. Cancer 2015, 112, 382-390. [CrossRef] [PubMed]
59. Ranasinghe,W.K.; Xiao, L.; Kovac, S.; Chang, M.; Michiels, C.; Bolton, D.; Shulkes, A.; Baldwin, G.S.; Patel, O. The role of hypoxia-inducible factor 1_ in determining the properties of castrate-resistant prostate cancers. PLoS ONE 2013, 8, e54251. [CrossRef] [PubMed]
60. Vergis, R.; Corbishley, C.M.; Norman, A.R.; Bartlett, J.; Jhavar, S.; Borre, M.; Heeboll, S.; Horwich, A.; Huddart, R.; Khoo, V.; et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008, 9, 342-351. [CrossRef]
61. Zhong, H.; Semenza, G.L.; Simons, J.W.; de Marzo, A.M. Up-regulation of hypoxia-inducible factor 1_ is an early event in prostate carcinogenesis. Cancer Detect. Prev. 2004, 28, 88-93. [CrossRef] [PubMed]
62. Zhong, H.; de Marzo, A.M.; Laughner, E.; Lim, M.; Hilton, D.A.; Zagzag, D.; Buechler, P.; Isaacs, W.B.; Semenza, G.L.; Simons, J.W. Overexpression of hypoxia-inducible factor 1_ in common human cancers and their metastases. Cancer Res. 1999, 59, 5830-5835. [PubMed]
63. Yasuda, M.; Shimizu, M.; Fujita, M.; Miyazawa, M.; Tang, X.; Kajiwara, H.; Osamura, R.Y.; Shoji, S.; Tokunaga, M.; Terachi, T. Usefulness of hypoxia inducible factor-1_ in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy. Cancer Detect. Prev. 2007, 31, 396-401. [CrossRef] [PubMed]
64. Ranasinghe, W.K.; Sengupta, S.; Williams, S.; Chang, M.; Shulkes, A.; Bolton, D.M.; Baldwin, G.; Patel, O. The effects of nonspecific HIF1_ inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med. 2014, 3, 245-251. [CrossRef] [PubMed]
65. Platz, E.A.; Yegnasubramanian, S.; Liu, J.O.; Chong, C.R.; Shim, J.S.; Kenfield, S.A.; Stampfer, M.J.; Willett, W.C.; Giovannucci, E.; Nelson, W.G. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 2011, 1, 68-77. [CrossRef] [PubMed]
66. Kitajima, Y.; Miyazaki, K. The critical impact of HIF-1_ on gastric cancer biology. Cancers 2013, 5, 15-26. [CrossRef] [PubMed]
67. Pouyssegur, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441, 437-443. [CrossRef] [PubMed]
68. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732. [CrossRef] [PubMed]
69. Harris, A.L. Hypoxia-A key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38-47. [CrossRef] [PubMed]
70. Stewart, G.D.; Ross, J.A.; McLaren, D.B.; Parker, C.C.; Habib, F.K.; Riddick, A.C. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. 2010, 105, 8-13. [CrossRef] [PubMed]
71. Deep, G.; Panigrahi, G.K. Hypoxia-induced signaling promotes prostate cancer progression: Exosomes role as messenger of hypoxic response in tumor microenvironment. Crit. Rev. Oncog. 2015, 20, 419-434. [CrossRef] [PubMed]
72. Fukuda, R.; Kelly, B.; Semenza, G.L. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003, 63, 2330-2334. [PubMed]
73. Krishnamoorthy, S.; Jin, R.; Cai, Y.; Maddipati, K.R.; Nie, D.; Pages, G.; Tucker, S.C.; Honn, K.V. 12-Lipoxygenase and the regulation of hypoxia-inducible factor in prostate cancer cells. Exp. Cell Res. 2010, 316, 1706-1715. [CrossRef] [PubMed]
74. Krishnamoorthy, S.; Honn, K.V. Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment. Cancer Metastasis Rev. 2011, 30, 613-618. [CrossRef] [PubMed]
75. Liu, X.H.; Kirschenbaum, A.; Yao, S.; Stearns, M.E.; Holland, J.F.; Claffey, K.; Levine, A.C. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin. Exp. Metastasis 1999, 17, 687-694. [CrossRef] [PubMed]
76. Liu, X.H.; Kirschenbaum, A.; Lu, M.; Yao, S.; Dosoretz, A.; Holland, J.F.; Levine, A.C. Prostaglandin E2 induces hypoxia-inducible factor-1_ stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. 2002, 277, 50081-50086. [CrossRef] [PubMed]
77. Ader, I.; Brizuela, L.; Bouquerel, P.; Malavaud, B.; Cuvillier, O. Sphingosine kinase 1: A new modulator of hypoxia inducible factor 1_ during hypoxia in human cancer cells. Cancer Res. 2008, 68, 8635-8642. [CrossRef] [PubMed]
78. Semenza, G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29, 625-634. [CrossRef] [PubMed]
79. Bensaad, K.; Favaro, E.; Lewis, C.A.; Peck, B.; Lord, S.; Collins, J.M.; Pinnick, K.E.;Wigfield, S.; Buffa, F.M.; Li, J.L.; et al. Fatty acid uptake and lipid storage induced by HIF-1_ contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014, 9, 349-365. [CrossRef] [PubMed]
80. Huang, D.; Li, T.; Li, X.; Zhang, L.; Sun, L.; He, X.; Zhong, X.; Jia, D.; Song, L.; Semenza, G.L.; et al. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep. 2014, 8, 1930-1942. [CrossRef] [PubMed]
81. Metallo, C.M.; Gameiro, P.A.; Bell, E.L.; Mattaini, K.R.; Yang, J.; Hiller, K.; Jewell, C.M.; Johnson, Z.R.; Irvine, D.J.; Guarente, L.; et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481, 380-384. [CrossRef] [PubMed]
82. Sun, R.C.; Denko, N.C. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 2014, 19, 285-292. [CrossRef] [PubMed]
83. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177-185. [CrossRef] [PubMed]
84. Furuta, E.; Pai, S.K.; Zhan, R.; Bandyopadhyay, S.;Watabe, M.; Mo, Y.Y.; Hirota, S.; Hosobe, S.; Tsukada, T.; Miura, K.; et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of AKT and sterol regulatory element binding protein-1. Cancer Res. 2008, 68, 1003-1011. [CrossRef] [PubMed]
85. Mylonis, I.; Sembongi, H.; Befani, C.; Liakos, P.; Siniossoglou, S.; Simos, G. Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression. J. Cell Sci. 2012, 125, 3485-3493. [CrossRef] [PubMed]
86. Jiang, L.; Greenwood, T.R.; Artemov, D.; Raman, V.; Winnard, P.T., Jr.; Heeren, R.M.; Bhujwalla, Z.M.; Glunde, K. Localized hypoxia results in spatially heterogeneous metabolic signatures in breast tumor models. Neoplasia 2012, 14, 732-741. [CrossRef] [PubMed]
87. Glunde, K.; Shah, T.; Winnard, P.T., Jr.; Raman, V.; Takagi, T.; Vesuna, F.; Artemov, D.; Bhujwalla, Z.M. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 _ signaling in a human prostate cancer model. Cancer Res. 2008, 68, 172-180. [CrossRef] [PubMed]
88. Kourti, M.; Ikonomou, G.; Giakoumakis, N.N.; Rapsomaniki, M.A.; Landegren, U.; Siniossoglou, S.; Lygerou, Z.; Simos, G.; Mylonis, I. CK1_ restrains lipin-1 induction, lipid droplet formation and cell proliferation under hypoxia by reducing HIF-1_/ARNT complex formation. Cell Signal. 2015, 27, 1129-1140. [CrossRef] [PubMed]
89. Kalousi, A.; Mylonis, I.; Politou, A.S.; Chachami, G.; Paraskeva, E.; Simos, G. Casein kinase 1 regulates human hypoxia-inducible factor HIF-1. J. Cell Sci. 2010, 123, 2976-2986. [CrossRef] [PubMed]
90. Qiu, B.; Ackerman, D.; Sanchez, D.J.; Li, B.; Ochocki, J.D.; Grazioli, A.; Bobrovnikova-Marjon, E.; Diehl, J.A.; Keith, B.; Simon, M.C. HIF2α-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 2015, 5, 652-667. [CrossRef] [PubMed]
91. Azmi, A.S.; Bao, B.; Sarkar, F.H. Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev. 2013, 32, 623-642. [CrossRef] [PubMed]
92. Hoshino, A.; Costa-Silva, B.; Shen, T.L.; Rodrigues, G.; Hashimoto, A.; Tesic, M.M.; Molina, H.; Kohsaka, S.; Di, G.A.; Ceder, S.; et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015, 527, 329-335. [CrossRef] [PubMed]
93. Ramteke, A.; Ting, H.; Agarwal, C.; Mateen, S.; Somasagara, R.; Hussain, A.; Graner, M.; Frederick, B.; Agarwal, R.; Deep, G. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol. Carcinog. 2015, 54, 554-565. [CrossRef] [PubMed]
94. Tadokoro, H.; Umezu, T.; Ohyashiki, K.; Hirano, T.; Ohyashiki, J.H. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 2013, 288, 34343-34351. [CrossRef] [PubMed]
95. Umezu, T.; Tadokoro, H.; Azuma, K.; Yoshizawa, S.; Ohyashiki, K.; Ohyashiki, J.H. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood 2014, 124, 3748-3757. [CrossRef] [PubMed]
96. Wang, T.; Gilkes, D.M.; Takano, N.; Xiang, L.; Luo, W.; Bishop, C.J.; Chaturvedi, P.; Green, J.J.; Semenza, G.L. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. USA 2014, 111, E3234-E3242. [CrossRef] [PubMed]
97. King, H.W.; Michael, M.Z.; Gleadle, J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12, 421. [CrossRef] [PubMed]
98. Yang, Y.; Yang, X.; Yang, Y.; Zhu, H.; Chen, X.; Zhang, H.;Wang, F.; Qin, Q.; Cheng, H.; Sun, X. Exosomes: A promising factor involved in cancer hypoxic microenvironments. Curr. Med. Chem. 2015, 22, 4189-4195. [CrossRef] [PubMed]
99. Sano, S.; Izumi, Y.; Yamaguchi, T.; Yamazaki, T.; Tanaka, M.; Shiota, M.; Osada-Oka, M.; Nakamura, Y.; Wei, M.; Wanibuchi, H.; et al. Lipid synthesis is promoted by hypoxic adipocyte-derived exosomes in 3T3-L1 cells. Biochem. Biophys. Res. Commun. 2014, 445, 327-333. [CrossRef] [PubMed]
100. Li, L.; Li, C.;Wang, S.;Wang, Z.; Jiang, J.;Wang,W.; Li, X.; Chen, J.; Liu, K.; Li, C.; et al. Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype. Cancer Res. 2016, 76, 1770-1780. [CrossRef] [PubMed]
101. Berchem, G.; Noman, M.Z.; Bosseler, M.; Paggetti, J.; Baconnais, S.; Le, C.E.; Nanbakhsh, A.; Moussay, E.; Mami-Chouaib, F.; Janji, B.; et al. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-_ and miR23a transfer. Oncoimmunology 2016, 5, e1062968. [CrossRef] [PubMed]
102. Record, M.; Carayon, K.; Poirot, M.; Silvente-Poirot, S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim. Biophys. Acta 2014, 1841, 108-120. [CrossRef] [PubMed]